The gravitational pull is unmistakable. The Westin St. Francis remains the symbolic center of power, where scale dominates the conversation and capital moves in large increments. However, innovation, from the concept of a molecule or engineering marvel, rarely begins at scale. It starts with a question, a patient-care frustration, a molecular insight and a small group of people willing to compress years of work into minutes of explanation.

That is why the Biotech Showcase matters. It’s why it continues to thrive just off the main stage. Like off-Broadway, this is where blockbusters are discovered.

Seven Minutes to Be Understood

I spent part of the day sitting in one room at the Biotech Showcase, listening to a succession of rapid-fire presentations, each lasting seven minutes per company. The room was only half full, but it was intensely attentive. This was not casual listening. This was evaluative listening.

Companies including OrisDx, IowaiBIO Inc., Endure Biotherapeutics, SIvEC Biotechnologies, Frezent, Sideral Therapeutics, Courative Inc., and others each delivered a tightly constructed narrative of carefully curated slides: the unmet clinical need, the scientific or molecular approach, progress to date and the precise inflection point ahead. Most importantly, resources needed for the next stage of development.

What made these presentations compelling was not polish, it was clarity. There was no time to hide behind jargon or aspiration. Seven minutes forces discipline. It reveals whether a team truly understands its own story. For investors or biopharma partners in the room, it quickly answers the most important question: Is this something I want to continue discussing?

That is the essence of a productive dating game. Not every conversation leads to a match, but the right ones unmistakably spark an attraction.

Why This Room Exists at All

The Biotech Showcase works because it understands timing and intent. Seed and early-stage companies do not come to San Francisco in January to compete with global pharmaceutical announcements. They come because the people who can change their trajectory are already in the city and already thinking about what comes next.

J.P. Morgan Healthcare Week is where the industry takes stock of itself. Large companies outline business plan priorities. Investors recalibrate portfolios. Strategies are stress-tested. In that context, the Biotech Showcase becomes a natural counterbalance: a place where emerging science is introduced not as speculation, but as possibility.

There is also quiet wisdom in the Showcase’s decision to record and share presentations after the event. In a week where schedules overlap and choices are constant, the ability to revisit a story matters. Conversations that begin in a room can continue weeks later, grounded in something concrete and lasting. That continuity is how relationships form—and how trust accumulates.

The City Becomes the Platform

What is easy to overlook from the outside is how completely San Francisco itself becomes part of the infrastructure during this week. Beyond the formal stages, firms across the ecosystem host companies in nearby venues, creating dozens of smaller hubs within walking distance of one another.

At places like the Marines’ Memorial Club, companies are hosted quietly and efficiently, often fifteen or so at a time, by firms such as FINN Partners, alongside others working behind the scenes to support emerging science during the week. During the course of J.P. Morgan Week, these companies may hold more than 200 conversations with analysts, investors, and media representatives. No banners. No spectacle. Just focused, purposeful, personalized dialogue.

This distributed model works because it mirrors how decisions are actually made, not in a single dramatic moment, but through repeated, informed exchanges that foster knowledge and confidence.

When the day winds down, the city shifts again. Evenings during J.P. Morgan Week are reserved for receptions hosted by banks, global companies, industry groups, and even trade commissions from countries such as the UK, including the UK Bioindustry Association. These gatherings are not afterthoughts. They are where formality loosens, where introductions give way to relationships, and where ideas heard earlier in the day are tested in conversation. Science meets context. Strategy meets personality.

When AI Enters the Dating Pool

One of the most notable developments this year is the growing presence of AI companies entering this ecosystem alongside emerging biotech companies—firms such as Briya.Health demonstrates how AI is no longer merely orbiting the life sciences; it is now deeply embedded within them.

Early-stage biotech is data-rich and time-poor. They generate complex, unstructured information long before scale or certainty arrives. AI platforms that can surface insight, reduce friction, and accelerate decision-making change the nature of early collaboration.

When AI innovators and biotech founders encounter one another during this week—often in the same rooms, at the same receptions, and in the same corridors—the conversation accelerates. What might have taken months of coordination elsewhere can happen organically here. That is not a coincidence. It is designed.

Why This Week Still Matters

Events like the Biotech Showcase, alongside complementary forums such as 1BusinessWorld’s Global BioInnovation Forum, emerge because they recognize how innovation actually drives progress. They realize that timing matters: place matters and proximity matters.

These gatherings do not compete with J.P. Morgan Healthcare Week; they complete it. Together, they create a comprehensive view of the health innovation lifecycle, from initial insight to global execution.

What I witnessed in that half-filled room was not hype. It was intent. Seven minutes at a time, company after company made a case—not just for funding, but for belief.

That is why the Biotech Showcase remains exactly what its name promises: a showcase of possibilities. And why, in the great dating game of health innovation, does it remain one of the most honest and productive places to begin?

The post The Best Dating Game in Health Innovation Happens Just Off the Main Stage appeared first on Medika Life.

Rare disease treatment is characterized by its numerous challenges, stemming from an overall lack of awareness across the healthcare landscape. This issue becomes a waterfall, trickling down and affecting crucial nodes of the healthcare value chain, such as regulations, existing healthcare infrastructure, and affordability, before it can even potentially reach patients. Hence, the cooperation of the public and private sectors with a firm basis in knowledge sharing and education is required to alleviate these multifaceted challenges brought from a lack of awareness.

The Root of Awareness  

Rare diseases are defined by their generally low population impact, with many markets agreeing to a ratioed figure, such as one patient per every 2,000 in a population. The rarity of such diseases results in a lack of awareness among both the general public and the healthcare practitioner community. This awareness gap translates into a significant challenge in patients receiving an accurate diagnosis. Combined with the relatively few specialized medical personnel for such diseases, this can lead to misdiagnosis or delayed referrals, resulting in an average time to receive a final diagnosis of up to 5 years. By this time, some rare diseases can cause significant distress, such as Leber hereditary optic neuropathy (LHON), which can cause vision loss in a matter of months if left untreated.

Patients face a journey of medical uncertainty, fiscal difficulties, and personal challenges. These issues are often exacerbated by healthcare systems that struggle to accurately and promptly diagnose such rare conditions.

Point-to-Point Hurdles in Medication Access

Across markets, the rare disease medication issue also has to contend with more tangible and operational concerns stemming from the lack of awareness. From a regulatory standpoint, the lack of rare disease understanding can lead to regulations being under equipped to address medication access. This is doubly so for more challenging regulatory landscapes, such as across APAC’s complex and fragmented market environment, where general healthcare accessibility can already prove to be a hurdle due to a combination of socioeconomic and geopolitical factors. This can lead rare diseases and their medications to be an underserved area, while more widely common health concerns are prioritized.

A key driver of healthcare access is the underlying infrastructure powering the supply chain, ensuring the distribution of medication to patients. Similar to regulations, supply chain systems can vary vastly in complexity, particularly when across challenging geography and when specialised logistics, such as cold chain solutions, are needed to handle sensitive medication. These can culminate in much-needed investment into supply chain infrastructure. For example, in APAC markets, such as Thailand, DKSH has established a network of satellite distribution centers that can provide last-mile delivery of sensitive medications to underserved areas in a short period of time.

Regulatory complexities and supply chain infrastructure aside, the barrier to rare disease medication accessibility most often felt by patients is the affordability of treatments. The high cost of rare disease treatment options is critical, with some reaching over a million dollars for annual or one-time treatment. The issue of cost is more amplified in regions like APAC, where many markets have less robust public health insurance or social support systems, placing a financial strain on patients, even when access is just within reach.

This collection of barriers to accessing rare disease medications can be daunting from the outset. As a challenge of global concern, addressing it requires a unified approach that combines in-market and industry expertise, all in service of bringing medication to underserved patients.

The Power of Collaboration

The unique challenges of rare diseases are too great for any single entity to tackle alone. Bridging this gap through collaboration is paving the way forward, with public-private partnerships (PPPs) emerging as a core means for success. These partnerships bring together government agencies, pharmaceutical companies, academic institutions, and patient advocacy groups to share expertise, resources, and risk. For instance, in the APAC region, initiatives like the APEC Action Plan on Rare Diseases have provided a framework for member economies to accelerate efforts in this area, including the promotion of multisectoral collaborations. Regional alliances, such as the Asia Pacific Alliance for Rare Disease Organizations (APARDO), have done valuable work in collaborating with advocacy groups to raise awareness about these conditions. On an organizational level, there are also healthcare partners, such as DKSH, who work with firms, such as Kyowa Kirin, to bring rare disease medications to markets by utilizing in-market and regulatory expertise. Moreover, DKSH’s local teams have strong market knowledge, enabling them to offer clients and customers expert advice on local regulation.

This collaborative approach is crucial for streamlining the regulatory process for rare disease medications, also known as orphan drugs. Governments, including many in Asia, have introduced specific regulations and incentives to encourage the development of rare disease medication. These include Orphan Drug Designations (ODD) that provide much-needed support, such as tax credits for clinical research. Beyond these incentives, regulatory bodies are considering a greater reliance on evidence from expanded access programs. This allows for the use of data from a smaller patient pool, which is often the only available source of information for such rare conditions, thereby accelerating the review and approval process.

From a patient perspective, financial aid is of vital importance and an area where collaboration is key. The high cost of treatments for rare diseases necessitates innovative funding models beyond traditional public insurance. One effective model gaining traction in APAC is the establishment of dedicated funds, supported by a combination of public and private contributions. Singapore’s Rare Disease Fund (RDF) is a prime example, where community donations are matched by the government at a significant ratio. This model provides long-term financial support for patients, while encouraging a sense of shared responsibility across society. Similarly, patient access schemes and managed access programs are being implemented to ensure affordability and controlled access to therapies before full reimbursement is in place. These schemes can be tailored to individual patient needs and help bridge the gap between regulatory approval and widespread access.

Ultimately, the future of rare disease medication accessibility rests on a unified, multi-stakeholder ecosystem. By building on collaborative frameworks, optimizing regulatory pathways, and pioneering innovative funding mechanisms, the healthcare landscape can be transformed. Beyond raising awareness, there is an opportunity to create a robust, equitable, and sustainable system that ensures no patient is left behind, regardless of the rarity of their condition.

The post Treating Rare Diseases: The Challenge of Access appeared first on Medika Life.

I was standing in my kitchen at 1:07 a.m., the only illumination a cold rectangle from the refrigerator.

It felt like a reversed Caravaggio scene. Darkness everywhere, a harsh pool of light on a plate of leftovers.

I was not hungry.

The light wired me awake. It felt like an invitation to eat.

I am a radiation oncologist.

I discuss circadian clocks with patients more often than most in my specialty because I’ve seen, over decades, how sleep, light, food timing, stress, and movement influence recovery, inflammation, and weight.

When you sit in a treatment room for a long enough time, you start to notice patterns.

People who live in bright evenings and dim mornings often struggle with appetite, cravings, and maintaining a healthy body composition.

They are swimming upstream against their biology.

This is the essay I wish someone had handed me ten years ago.

Light is not neutral.

It is a metabolic signal.

And the way we dose it each day can quietly nudge our insulin, our melatonin, our leptin and ghrelin, our brown fat, and even the clocks inside our liver and pancreas.

Let me show you how to use that to your advantage.

The Night I Realized Light Exposure Could Make You Fat.

In the clinic, I began asking a new question: not just how many hours you sleep, but how much light hits your eyes after sunset.

Most patients stared. Then came the stories: three glowing screens, bright LEDs in the bedroom, a dog walk under sodium street lamps.

Late light. Fragmented sleep.

Late eating. Creeping weight.

Our fat cells tell time. So do our mitochondria. So does your gut microbiome.

Light at the wrong time scrambles those clocks. Scrambled clocks change how you store energy.

Your Fat Has a Clock: Circadian Rhythm, Metabolism, and Weight Gain.

Every cell in your body keeps time.

Morning light anchors the master clock in your brain, which in turn syncs the clocks in your organs and fat cells.

Weak morning light and strong evening light throw those clocks out of phase.

The result is a subtle metabolic jet lag that never ends.

Quiet jet lag doesn’t show up on your calendar. It shows up on your scale.

Melatonin, insulin, and the late-night snack

Melatonin is not just a sleep hormone.

It cross-talks with insulin.

When melatonin levels are high, your ability to handle glucose decreases.

That is adaptive if you are asleep.

It is not adaptive if you are scrolling with a bowl of cereal near midnight.

Bright light at night suppresses melatonin, delays sleep, and shifts appetite later.

You wake underslept, with more ghrelin, less leptin, and a stronger drive to eat ultraprocessed food.

Rinse. Repeat.

Want to reset your metabolism?
→ Get my Micro-Habits bundle for daily light protocols, circadian checklists, and the exact scripts I give patients.

Morning light is metabolic medicine.

Ten minutes of unfiltered outdoor light soon after waking can move your circadian clock earlier, deepen your sleep that night, and improve next-day insulin sensitivity.

Morning light is rich in wavelengths your brain needs to set the day. Indoors, even bright-looking rooms are often one or two orders of magnitude dimmer than outside.

Your brain can tell the difference. So can your pancreas.

If you do one thing after reading this, step outside within 30 minutes of waking.

If it is cloudy, go anyway. If it is winter, aim longer. Treat it as you would a prescription.

Darkness is a habit

We talk about sleep hygiene.

We rarely talk about darkness hygiene.

Your retina is exquisitely sensitive to blue light, but even dim bulbs can disrupt your sleep cycle.

Swap bedside LEDs for warm, low-lux bulbs.

Set your phone to grayscale and enable a screen sunset. Cover the power lights with black tape.

Close the fridge quickly. Dim your home two hours before bed until it resembles a Rembrandt painting.

Your metabolism prefers Rembrandt over Times Square.

What I tell patients in the clinic

1. See the morning light early and consistently.
2. Eat most of your calories in the daylight zone.
3. Dim the house two hours before you want to sleep.
4. Stop eating at least two to three hours before going to bed.
5. Keep the bedroom dark, cool, and free of screens.
6. Anchor wake time seven days a week.
7. Move your body in the day, not at midnight.
8. Treat shift work like altitude. You need extra recovery, extra discipline, and a plan.

Micro-habits that fix your light diet

• Lux-before-latte rule: no coffee until you have been outside.
• Two-switch protocol: one button that turns off all bright overheads at 8 p.m., one that turns on warm lamps. Make darkness effortless.
• Yellow-card your phone: night shift mode, grayscale, and a screen curfew you respect.
• Front-load protein: bigger breakfast and lunch, smaller dinner. Your insulin sensitivity is higher earlier.
• Walk after dinner: even ten minutes blunts the glucose spike and helps your clock wind down.
• Bedroom audit: cover LEDs, use blackout curtains, move chargers to the hallway.
• Weekend consistency: Social jet lag is a form of metabolic jet lag. Keep your wake time within 60 minutes of weekdays.

The lab evidence in plain English

Animal models demonstrate that mistimed light exposure leads to weight gain, even without consuming extra calories.

Human studies have linked nighttime light exposure to a higher BMI, poorer sleep, and worse glucose control.

Shift workers have higher risks of obesity, diabetes, and some cancers.

These conditions are not destiny. They are signals you can change.

If you still want numbers

Chronobiology papers repeatedly show that eating the same calories at night causes a higher postprandial glucose and insulin response than eating them in the morning.

Timed light therapy can correct delayed sleep phase and improve metabolic markers.

Dim light at night correlates with higher rates of depression and weight gain.

Again, correlation is not causation, but the mechanisms are biologically sound.

A one-week protocol to test on yourself

Day 1 to 2

• Wake at the same time both days.
• Get 15 minutes of outdoor light within 30 minutes of waking.
• Track meals. Eat 80 percent of calories by 4 p.m.
• Dim the house lights at 8 p.m. Aim for minimal screen time.
• Sleep in full darkness.

Day 3 to 7

• Extend morning light to 20 minutes.
• Add a 10-minute post-dinner walk.
• Keep dinner smallest and earliest.
• Keep wake time strict.
• Note morning hunger and energy. By day 4, many people report fewer nighttime cravings.

How this plays out in the real world

A patient with breast cancer told me she could not lose weight despite “doing everything right.”

She tracked calories, lifted weights, and avoided ultraprocessed foods. She also answered emails at midnight under bright LED downlights and ate a second dinner at 10:30 p.m.

We moved her dinner to 6 p.m., instituted a house-wide dim at 8 p.m., added morning light exposure, and asked her to maintain a stable wake time, even on weekends.

Six weeks later, she had lost six pounds without changing her total calorie intake.

Her sleep improved. Her cravings diminished.

The scale finally listened.

The broader stakes of light exposure and weight gain

We are the first species to flood the night with light and the day with dimness.

We built a 24-hour culture and then wondered why our biology pushed back.

Weight gain is not a character flaw.

It is often a circadian mismatch.

Fix the light. Observe the effects on hunger, sleep depth, glycemic control, and weight.

Final Thoughts

Light is a drug.

Dose it wisely.

Morning heals.

Evening disrupts.

Darkness is a habit, not a switch.

If your weight has been creeping up, remember this: your first diet is not on your plate.

It is in your eyes.

→ Want my full circadian reset, daily checklists, and Micro-Habits plan? Get the Micro-Habits bundle today.

→ Follow me here on Medium for more science-backed, story-driven guides to living longer and better.

Author bio: I am a radiation oncologist who writes daily about longevity, cancer prevention, and the small habits that change health trajectories.

The post The Strange Link Between Light Exposure and Weight Gain appeared first on Medika Life.

What Makes Stem Cells So Special?

Stem cells can become any cell type in your body, similar to blank pages in a book. Specific cells in your body have predetermined functions, such as muscle cells for movement or brain cells for thinking, but stem cells work differently. These stem cells stay undecided about their future roles. Their two unique abilities come from their capacity to reproduce endlessly and to transform into specialized cells when the body needs repairs. Whoever thought we would have a little medical mechanic industry waiting for us to give it the word?

The cells possess two distinct capabilities: they reproduce infinitely to generate additional stem cells, and they evolve into specific cells when the body requires maintenance. It seems the reservoir is never tapped out, as they are always replenished. Stem cells transform into skin cells when skin injuries occur. Stem cells may develop into heart muscle cells when the heart experiences damage. Almost miraculously, these cells can learn just about any function instantly.

I recall a biology professor explaining that implanting eye stem cells in someone’s abdomen would result in the development of a non-functioning eye. That sounds like something from a science fiction movie. But it might be possible.

Your Body’s Hidden Stem Cell Factories

Stem cells exist throughout the entire body as your internal repair team, which operates unnoticed. Bone marrow represents the most well-known stem cell habitat because it exists as a soft, jelly-like tissue inside bones. Blood stem cells reside in bone marrow to produce red blood cells for oxygen transport and white blood cells for infection defense, while making platelets for bleeding control.

But that’s just the beginning. The brain contains stem cells that have the potential to generate new brain cells. Neural stem cells (NSCs) are indeed found in the hippocampus, a brain region crucial for learning and memory. If they’re there, why can’t we use them? That’s one of the secrets that is still to be unlocked.

The skin contains stem cells, which serve two purposes: they repair injuries and maintain skin health. Each of the muscles, as well as the liver, fat tissue, and heart, possesses its individual stem cell populations.

The discovery of new stem cell sources continues to amaze scientists. Stem cells in newborn umbilical cord blood demonstrate powerful therapeutic potential against 80 different diseases. And the stem cells found in baby teeth have gained scientific interest due to their potential future medical applications.

From Lab Bench to Bedside: Real Treatments Today

Here’s where things get really exciting. Stem cell treatments have moved beyond science fiction because they currently save the lives of patients. Blood stem cell therapies show the greatest success in treating leukemia and lymphoma patients among other cancer types. Doctors perform stem cell transplants after chemotherapy destroys a patient’s blood system to establish a new system from scratch.

The FDA approved the first gene-edited stem cell treatment, Casgevy, in 2024, marking a significant achievement in medical history. This treatment process begins with blood stem cell collection from patients, followed by genetic correction through CRISPR technology and final cell reinsertion to treat sickle cell disease and beta-thalassemia, which have long caused suffering to thousands of patients.

Ryoncil marked a significant achievement when it became the initial stem cell treatment approved for children suffering from graft-versus-host disease. Transplanted cells sometimes attack patients’ bodies during graft-versus-host disease, but these unique stem cells function as a solution to reduce dangerous immune reactions.

Research on eye diseases represents one of the most promising areas of stem cell advancement. Scientists have discovered a method to develop light-sensitive cells from stem cells located at the back of the eye. Early clinical studies demonstrate that lab-grown cells can provide vision improvements to patients with age-related macular degeneration, which ranks as a primary cause of blindness.

The trial participant who joined the study experienced such a remarkable improvement in vision that he shifted from hand movement recognition to reading letters on an eye chart. The preliminary stage of these medical trials demonstrates potential to treat vision impairment for millions of affected people.

Healing Hearts and Fixing Brains

Stem cell research reaches its peak when scientists use these cells to treat the heart and brain, which are our two essential organs. Scientists continue their research to utilize stem cells for repairing damaged heart muscle tissue following heart attack events. Researchers in Japan currently perform stem cell-derived heart muscle cell injections into heart patients, which have produced promising initial outcomes.

Scientists also investigate stem cell-derived dopamine-producing cells for brain replacement therapy to treat Parkinson’s disease and other brain disorders where dopamine-producing cells gradually die out. The clinical trials conducted worldwide have proven safety standards for this procedure, while multiple patients report significant symptom relief from their conditions. If dopamine-producing cells can work with PD, how about mental disorders?

New exploratory investigations into potential applications of stem cells to treat ALS (Lou Gehrig’s disease), as well as spinal cord injuries and Alzheimer’s disease, have begun. Researchers continue to expand their studies because of promising early results from these experimental treatments,but the work must go on diligently, uninterrupted, due to a lack of research funding.

Growing Organs in the Lab

The most advanced stem cell research involves creating mini-organs through laboratory cultivation. Scientists currently conduct research on “organoids,” which are not a figment of science fiction. At the Mayo Clinic, alongside other institutions, researchers develop miniature versions of intestines, hearts, kidneys, and brain tissues from stem cells.

The miniature organs enable scientists to improve disease comprehension and facilitate secure drug testing. They can then utilize these laboratory-grown organs for preliminary drug assessments before moving forward to human trials. This method will significantly accelerate and enhance the safety of the new treatment development process.

The Numbers Tell an Incredible Story

Stem cell research has expanded at an incredible rate during recent years. The worldwide clinical trial number for stem cell products has reached 83, while researchers approved 115 trials during 2024. More than 1,200 patients have received experimental stem cell treatments, and researchers have administered over 100 billion stem cells during clinical trials without any major safety issues.

The stem cell therapy market projection indicates it will expand from $14 billion in 2023 to reach $49 billion by 2033. This monetary growth signifies the promise of new medical options for millions of patients who remain without effective treatment options for their diseases.

What This Means for You and Your Family

Most stem cell treatments remain experimental, but researchers continue to advance at an extraordinary rate. Clinical trials, together with new breakthroughs and patient hopefulness, increase every month. Medical researchers investigate stem cell applications for diabetes treatment, arthritis management, heart disease prevention, stroke treatment, spinal cord injury therapy, multiple sclerosis therapy, and various cancer types.

When pursuing stem cell treatment, choose established medical centers that offer FDA-approved procedures or participate in authorized clinical trials. Be cautious of medical clinics that advertise untested treatment methods as miracle solutions.

I have personally seen a friend’s family member be first drawn to Canada, then to Mexico, and finally to the Caribbean to seek treatment for his terminal cancer. The family spent hundreds of thousands of dollars, and he died.

The most beneficial aspect of stem cell research extends beyond disease treatment, as it reveals body healing processes and develops methods to enhance these natural recovery mechanisms. We are now looking at a new area of medicine, regenerative medicine. Scientists have discovered that stem cells serve a dual function by replacing damaged cells and releasing substances that promote the healing of other cells and minimize inflammation.

A Future Full of Hope

The present decade marks a remarkable period for stem cell research studies. Through improved understanding and advanced techniques, alongside gene editing technology, scientists can now achieve opportunities that were thought to be unattainable in the previous few years.

Researchers predict that stem cell treatments will become available for stroke recovery, spinal cord repair, organ transplant, and anti-aging purposes in the near future. Progress toward these advancements continues with each successful trial and new discovery, although we have not yet achieved this stage.

But the future is bright! The most inspiring element in this story lies in the fact that our bodies supply the answer to our medical challenges. Stem cell treatments consist of human body cells that scientists enhance and direct for therapeutic purposes. Medical efforts don’t battle against natural processes because we are learning to make better use of them. Each time I hear of an advance, it brings new enthusiasm for research, and the key is to keep funding this research because there is more to find.

Stem cells represent a unique prospect for future medical science to allow our body’s natural wisdom and healing capabilities to work alongside medical advancements to enhance human longevity and well-being. This discovery goes beyond good science because it represents authentic hope.

The post The Body’s Amazing Repair Crew: Stem Cells appeared first on Medika Life.

Q&A

Gil Bashe: You called Converge\OIST the “very first gathering.” Why did Okinawa feel like the right birthplace?

Yasushi Yamamoto: Yes, this is the very first gathering, and we named it Converge\OIST because I’m a big fan of ‘OIST’—the context of the birth, this location, these people. It was the right place and people, a great gathering, and a pleasure to meet old friends in such a beautiful, inspiring place.

Gil Bashe: Your career bridges Tokyo boardrooms and Jerusalem start-ups. Where did your obsession with “convergence” begin?

Yasushi Yamamoto: Innovation cannot be done in an isolated form; it should be done in collaboration with various fields. Professionals with beautiful résumés in Tokyo surround me, but many lack a broader vision. They are so good at something particular, yet it’s a pity they’re busy in silos. I saw the lack of collaboration and started my business, raising money from Japanese corporations for Israeli start-ups. That contrast—dinosaurs with big systems but little ‘challenging spirit’ versus entrepreneurs who ‘run and fix’—motivated me to build synergy between powerful pieces.

Gil Bashe: Modern medicine seems to multiply silos every year. How do you see convergence breaking that pattern?

Yasushi Yamamoto: Medicine has become hyper-specialized. We have gastroenterologists who only look at the upper esophagus or the colon, cardiologists in electrophysiology, and neurologists focused on one nerve pathway. They perfect an art, but they have blinders. Convergence is breaking down those walls.

Gil Bashe: Inviting violinists and AI ethicists to the same podium can feel radical. How did people react when you pitched this mix?

Yasushi Yamamoto: People would never believe me if I hadn’t done serious work in the previous decade. Thanks to that track record, we built trust. Gathering in Okinawa sounded out of context for many professionals, but it wasn’t curiosity but trust that made them come.

Gil Bashe: Every July, you disappear into Kyoto’s 1,200-year-old Gion festival to play the traditional Japanese flute. What does a month of music teach a CEO?

Yasushi Yamamoto: Back home, I’m participating and serving. When I set up my company, I realized it would never be greater than this festival. The experience makes me humble. I received a baton from previous generations and must pass it on to the next. After that month, I ask, ‘Two generations later, how will young people judge the work I’m doing now?’

Gil Bashe: You’ve spoken of building on three “wheels”: science, art, and philosophy. Where is Corundum on that journey?

Yasushi Yamamoto: We started in hardcore science and investment, then gradually expanded to art—like Leonardo da Vinci, artist and scientist in one person. In the coming three to five years, I will put the vehicle of philosophy on top. Combining great minds and spirit, we can create something AI alone cannot deliver.

Gil Bashe: What tangible outcomes do you want from Converge?

Yasushi Yamamoto: First, I want to support OIST, an institution I love. We held the first event there; followed by South by Southwest London. I want more gatherings in multiple locations, bringing talented people with good hearts.

Gil Bashe: You’ve set up subsidiaries for neuroscience, virtual mixed human-data AI, and the microbiome. Why those intersections?

Yasushi Yamamoto: Think of the gut–brain axis. Discovery comes from interaction: AI power, system biology, and the microbiome. Add the element of art to inspire other curious, intelligent people, and the community expands.

Gil Bashe: Food as medicine used to be folk wisdom; you’re turning it into data science. How?

Yasushi Yamamoto: We invested in a project from the Weizmann Institute—the deepest phenotype cohort, hundreds of people over 20 years with genes, metabolites, behavior, nutrition. We link ancient wisdom to ultra-modern science by layering AI on that dataset. We are converging the past, the future, and current ways of life.

Gil Bashe: Philosophy sounds noble, but ventures need cash. How do you square capital with conscience?

Yasushi Yamamoto: I strongly believe in setting vision on a solid philosophical idea, but also in the power of capital. Our job is to propose a hypothesis, bring capital, deploy people, and prove the hypothesis with action. So, we’re raising our next venture fund while creating the Corundum Convergence Institute, a U.S. 501(c)(3), as an alternative financing model to advance science.

CLOSING THOUGHTS

Yamamoto-san reframes the entrepreneur’s impossible triangle—mission, money, and meaning—into an orchestral score. Science provides the bass line, art supplies melody, philosophy sets tempo, and well-deployed capital funds the concert hall. As Converge expands from Okinawa to London and beyond, its founder is betting that harmony, not hierarchy, will unlock the next era of precision health.

The takeaway is disarmingly simple for the rest of us: when great minds tune their instruments to work in harmony, the walls separating our disciplines start to fall—and patients everywhere will hear the music of life-sustaining innovation.

According to Gil Granot Mayer, Executive Vice President, Technology Development & Innovation at OIST:

“In just two days, we managed to connect people from different disciplines and geographies, immersing them in the OIST spirit and Okinawa’s culture. From understanding the value of the long tail to different approaches to improving life through the Human Phenotype Project, or the understanding of a new aging mechanism associated with cell membrane damage. I hope that these new connections and cutting-edge talks will spark new collaborations and great results.”

The post Blending Renaissance Thinking and Collaborative Power to Address Global Health Challenges appeared first on Medika Life.

Higher scores for diet quality and greater consumption of shortfall nutrients, especially nutrients of public health concern, are associated with dietary patterns that are rich in canned and dry beans. Improved weight-related outcomes are also linked to bean dietary patterns. In essence, dietary recommendations for the United States should consider the nutritional and health advantages of encouraging more people to eat canned and dry beans.

But plant-based diets have some benefits that may surprise many. Reduced mortality from prostate cancer and improved ecological sustainability are only two of the several advantages of plant-based diets.

According to a recent study conducted by academics, beans, and peas are the most cost effective and environmentally friendly alternatives to meat and milk. Given the current emphasis on environmental and climate change, we must consider alternatives to our current meat-based diet and assess their value.

The study published in the PRNAS found that soybeans, peas, and beans, as well as other legumes, performed better than processed foods like veggie burgers and plant milks.

Even after considering possible savings and investments, lab-grown meat was the most ineffective substitute due to its expensive price tag and the absence of health advantages.

What’s This About “Pulses?”

Pulses have become less common in people’s everyday diets and the prevalence of chronic diseases has increased during the last century, both of which have altered people’s eating patterns. Whole grain and legume consumption is associated with improved cardiovascular, metabolic, and cognitive health as well as longer life expectancy, according to both a priori and a posteriori dietary patterns. Contrarily, cardiovascular disease and premature death have been linked to diets heavy in sugar, processed foods, and red meat.

Some examples of pulses are peas, beans, and lentils. As an illustration, while pea pods are legumes, the peas within them are the pulse. While most of us eat legumes for their seeds or pulses, the whole plant is used in agriculture for cover crops, cattle feed, and fertilizers. Pulses include beans of many varieties, including kidney, black, pinto, navy, chickpeas, and many more. (This information was sourced from: https://nutritionsource.hsph.harvard.edu/legumes-pulses/). But pulses aren’t the only thing to consider. For example, beans are “resistant starches” and that is the importance they bring to our diet.

Everyday foods often contain starch, a type of carbohydrate. After cellulose, it is the chemical component found in plants in the highest abundance. In its chemical form, starch consists of two molecules of monosaccharide. Starch falls into one of three types according to its physical and physiological characteristics: quickly digestible, slowly digested, or resistant starch. It was also discovered that resistant starch remained undigested. Research has shown that the gut microbial communities make use of these undigested carbohydrates. Here is where all the magic starts.

Resistant starch does not produce an increase in blood sugar levels since it is not broken down in the small intestine. Beneficial bacteria proliferate while harmful bacteria deplete as a result of fermentation in the large intestine, leading to an improvement in gut health. Glycemic management (especially important for diabetic patients) can be enhanced by promoting healthy gut bacteria. A reduction in cholesterol levels and the danger of colon cancer are among the other advantages of resistant starch. It also helps with constipation and both treats and prevents it. Because of its long fermentation process, resistant starch produces less gas than other fiber types.

Our best sources of resistant starch foods include:

• Plantains and green bananas (as a banana ripens, the starch changes to regular starch)
• Beans, peas, and lentils (white beans and lentils are the highest in resistant starch)
• Whole grains, including oats and barley
• Cooked and cooled rice. Why “cooled” rice? Because it increases the resistant starch content.

So, beans aren’t the only food with resistant starch qualities, but they are the easiest to obtain and least expensive when prepared in dried form. Canned beans may seem fine for quick meals, and that’s true, but they also may contain high levels of salt, which is unsuitable for anyone’s diet.

Concerned about your health and that of the plant? Reconsider a plant-based diet and beans as a staple in your meals.

The post Beans Are Now the Super Food That We All Need, So Get Ready for a New Diet appeared first on Medika Life.

I have about seven weeks to the competition.

This approach is my battle plan, not a quick fix.

Here are my five tips for getting rid of belly fat.

1. I Am Reducing Calories in a Smart Way

We’ve all heard the “eat less, move more” mantra, but it’s not about punishing yourself.

Generally, weight loss should lead to a drop in abdominal fat.

I target my entire body and health, not my belly in isolation.

I think of my body as an engine needing the right fuel to run efficiently.

Instead of drastic cuts, I focus on swapping out the junk for the good stuff.

The cutting phase is when I try to pile my plate with brightly colored, lean protein like chicken and fish and healthy fats from avocados and nuts.

This approach keeps me full and satisfied, which is key.

As the American memoirist, poet, and civil rights activist Maya Angelou observed,

“Nothing will work unless you do.”

And smartly doing it is even better.

2. Protein: My Belly Fat’s Kryptonite

Protein is my not-so-secret weapon.

It boosts those “full” hormones, keeping me away from the snack drawer. Less snacking means less belly fat.

I admit it’s not that simple.

I imagine protein as my body’s construction crew.

It repairs and builds muscle, which burns more calories.

As bodybuilder Arnold Schwarzenegger opined,

“Strength does not come from winning. Your struggles develop your strengths. When you go through hardships and decide not to surrender, that is strength.”

Protein helps me build that strength and, in turn, helps me shed belly fat.

3. Fruits and Vegetables: Nature’s Candy & Cleansers

Then, there is the nutrient-dense nature and fiber content of fruits and vegetables.

Fruits and vegetables keep my gut happy while filling me with fewer calories.

I think of fruits and vegetables as nature’s multivitamins.

My apologies, but I can’t resist loading today’s piece with quotes, so here is another one (from Hippocrates):

“Let food be thy medicine and medicine be thy food.”

4. Move Your Body, Change Your Body.

Small changes — like taking the stairs or parking further away — add up.

Exercise Snacks: 7 Tiny Workouts for Big Results

medium.com

However, I aim for a weekly minimum of 300 minutes of moderate activity for serious fat loss.

That’s double the standard recommendation, but I aim for a competition-ready physique.

I also incorporate HIIT (high-intensity interval training) — short bursts of intense activity — to burn calories.

HIIT and Fitness: The Verdict is In

DO SHORTER VERSIONS of high-intensity interval training improve health? Researchers have recently analyzed short…

medium.com

Think of exercise as your daily dose of energy and confidence.

You guessed it: I am going to offer another quote, this one from Muhammad Ali:

“I hated every minute of training, but I said, ‘Don’t quit. Suffer now and live the rest of your life as a champion.’”

5. Strength Training: Build Muscle and Burn Fat

Lifting weights isn’t just for building muscle; it helps shrink belly fat too.

Combining aerobic and strength training leads to the biggest reduction in visceral fat for me.

Think of strength training as building your fat-burning furnace.

Yes, I offer another quote!

Henry Ford:

“Whether you think you can, or you think you can’t — you’re right.”

So think of strength training as a way to say “I can” to a leaner, healthier you.

Bonus Tips for Maximum Impact

Finally, here are some additional things I do to get my abs ripped:

• Limit sugary drinks: Water is my best friend. I ditch the sugary sodas and juices.
• Get sugar from whole foods: An apple is better than apple juice. Fiber is my friend.
• I avoid ultra-processed foods, including crackers, chips, and frozen dinners, which contain unhealthy fats, sugar, and sodium.
• Add in healthy fats: Nuts and avocados reduce inflammation.
• Eat more probiotic-rich foods: Yogurt, kefir, and sauerkraut improve gut health.
• Limit stress: Cortisol is a belly fat magnet. Yoga and meditation may help.
• Focus on sleep: I aim for 7 to 8 hours of quality sleep.

Consistency is key.

These tips aren’t magic bullets but are a solid plan for reaching my fitness goals.

The post 5 Tips For Getting Rid of Belly Fat appeared first on Medika Life.

GLP-1 agonists have also shown promise in reducing the risk of major adverse cardiovascular events, such as stroke and heart attack. This adds to their potential benefits in managing obesity and its related health complications.

Clinical Trial of Semaglutide and Bimagrumab

One promising avenue of research involves combining existing GLP-1 receptor agonists with experimental drugs designed to preserve muscle mass. A clinical trial, known as the BELIEVE Phase 2b study, is currently underway to test the combination of semaglutide and bimagrumab. Bimagrumab is a first-in-class, fully humanized monoclonal antibody developed by Versanis Bio, a clinical-stage biopharmaceutical company recently acquired by Eli Lilly. It targets activin type II receptors, which play a role in regulating muscle growth and fat storage. This trial aims to assess the efficacy and safety of bimagrumab in preserving or increasing muscle mass while promoting weight loss with semaglutide in non-diabetic patients with overweight or obesity.

To be eligible for the BELIEVE study, participants must have a body mass index (BMI) greater than or equal to 30, or greater than or equal to 27 with one or more obesity-related comorbidities. Key exclusion criteria include a history of hypersensitivity to monoclonal antibody drugs, treatment with any medication for obesity within 30 days before screening, and a diagnosis of diabetes requiring current use of any antidiabetic drug.

Pre-clinical studies have shown that blocking activin type II receptors with bimagrumab leads to increased lean mass and decreased fat mass in mice. In a Phase 2 study, bimagrumab produced a 22% reduction in fat mass and a 4.5% increase in lean mass in patients with type 2 diabetes and obesity. Notably, no weight regain was observed after stopping bimagrumab treatment, unlike the rebound effect often seen with GLP-1 therapies. This suggests that bimagrumab may offer long-term benefits in maintaining weight loss even after treatment cessation.

The ongoing clinical trial will provide valuable insights into the potential of combining semaglutide and bimagrumab to achieve superior fat loss while preserving muscle mass. This combination therapy could offer a more comprehensive weight management approach, addressing fat loss and muscle preservation.

Semaglutide and Bimagrumab: Mechanisms of Action

Semaglutide and bimagrumab work through distinct mechanisms to achieve their therapeutic effects. Semaglutide, a GLP-1 receptor agonist, mimics the action of GLP-1, a natural gut hormone crucial in regulating blood sugar and appetite. GLP-1 agonists work by

• Triggering insulin release from the pancreas
• Blocking glucagon secretion
• Slowing stomach emptying
• Increasing feelings of fullness

Semaglutide helps lower blood sugar levels, reduce appetite, and promote weight loss by mimicking these effects.

Bimagrumab, on the other hand, is a human monoclonal antibody directed against type II activin receptors (ActRII). Upon administration, bimagrumab binds to ActRII, which prevents binding the natural ligands, myostatin and activin, to activin receptors and blocks ActRII-mediated signalling. This increases protein synthesis, decreases protein degradation, stimulates skeletal muscle cell growth, and increases muscle function and strength10. Overstimulation of the ActRII-mediated signalling pathway is associated with muscle loss and weakness.

Other Anti-Obesity Drugs in Development

The success of semaglutide and tirzepatide has fueled a surge in the development of new anti-obesity drugs. These drugs target various biological pathways and aim to improve upon the limitations of existing therapies. Targeting multiple pathways simultaneously could allow for lower doses that achieve the same weight loss with fewer side effects. Some of the key areas of development include:

GLP-1 and GIP Receptor Agonists

Tirzepatide is a dual GLP-1 and GIP receptor agonist that has shown superior weight loss results compared to semaglutide in a large head-to-head trial by Eli Lilly. Participants who took tirzepatide lost an average of 20% of their body weight, outpacing the 14% reduction achieved with semaglutide. Tirzepatide is already available under the brand names Mounjaro and Zepbound.

There are two main strategies for modulating GIP activity: activation and blocking. While both approaches can lead to weight loss, they have different potential benefits and drawbacks. As seen with tirzepatide, GIP activation can further enhance energy metabolism and promote weight loss. However, some concerns blocking GIP signalling could adversely affect bone health, as GIP also plays a role in bone metabolism.

Amylin Analogues

Amylin is a hormone co-secreted with insulin that regulates blood sugar and appetite. CagriSema, a combination therapy developed by Novo Nordisk that pairs a long-acting analogue of amylin (cagrilintide) with semaglutide, has shown promising results in clinical trials. Participants in a 68-week, phase 3 trial lost an average of nearly 23% of their body weight.

Glucagon and GLP-1 Receptor Co-agonists

Glucagon is a hormone that raises blood sugar levels, while GLP-1 lowers them. Combining these two hormones in a single drug could offer a balanced approach to weight loss by increasing energy expenditure while maintaining blood sugar control. Survodutide, a glucagon and GLP-1 receptor co-agonist developed by Boehringer Ingelheim, is currently in clinical trials.

Triple-Hormone Receptor Agonists

Retatrutide, a triple-hormone receptor agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors, has shown impressive weight loss results in Phase 2 trials. This drug, dubbed “triple G,” delivered an average weight reduction of 24% after 48 weeks, setting a new benchmark for obesity treatments.

Alternative Delivery Methods for Anti-Obesity Drugs

Companies are also exploring alternative delivery methods to once-weekly injections, which can be challenging to incorporate into people’s routines and come with manufacturing challenges. Once-monthly injectables are in the works, but oral formulations of GLP-1 receptor agonists, such as orforglipron produced by Eli Lilly, could arrive first.

Another potential alternative is oral semaglutide. In a phase 3 study called OASIS 1, people taking oral semaglutide 50 mg once daily lost up to 15% of their initial body weight after about 15 months (68 weeks) of use. This is comparable to the weight loss benefits of Wegovy, the injectable version of semaglutide.

Potential Side Effects of Anti-Obesity Drugs

While anti-obesity drugs offer a promising approach to weight management, they can also cause side effects. Some of the common side effects of GLP-1 receptor agonists include nausea, vomiting, diarrhoea, and constipation. More serious side effects, such as pancreatitis and gallbladder problems, are rare but can occur.

Specific side effects associated with semaglutide include nausea, vomiting, diarrhoea, abdominal pain, constipation, heartburn, and burping. In rare cases, semaglutide can cause more serious side effects such as pancreatitis, kidney problems, and changes in vision.

Tirzepatide can cause similar side effects, including nausea, diarrhoea, decreased appetite, vomiting, constipation, and stomach pain. Serious side effects, such as pancreatitis, gallbladder problems, and low blood sugar, can also occur.

Another concern with GLP-1 and GIP drugs is the potential risk of pulmonary aspiration during anaesthesia. These drugs can cause delayed gastric emptying, which may increase the risk of residual gastric contents despite preoperative fasting. This can lead to aspiration, where food or liquid gets into the lungs during surgery.

The increased demand for GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists has led to temporary product shortages. This has resulted in the emergence of compounded formulations of these drugs, which produce entities that bypass regulatory measures. The American Diabetes Association recommends against using non-FDA-approved compounded GLP-1 and dual GIP/GLP-1 receptor agonist products due to concerns regarding their safety, quality, and effectiveness. The FDA has also issued an alert on dosing errors associated with compounded semaglutide injectable products, which have led to adverse events and hospitalisations in some cases.

It is important to note that the potential side effects of anti-obesity drugs vary depending on the specific medication and individual factors. Patients should discuss these medications’ possible risks and benefits with their healthcare provider to determine the most appropriate treatment option.

Alternative Treatments for Obesity: Bariatric Surgery

For some individuals, bariatric surgery may be an alternative treatment option for obesity. Bariatric surgery involves making changes to your digestive system to help you lose weight. It is typically considered for people with a BMI of 40 or higher or those with a BMI of 35 or higher who have obesity-related health problems.

There are several types of bariatric surgery, including

• Roux-en-Y gastric bypass: This procedure involves creating a small pouch at the top of the stomach and connecting it directly to the small intestine, bypassing most of the stomach and the first section of the small intestine
• Sleeve gastrectomy: This procedure involves removing about 80% of the stomach, leaving a long, tube-like pouch
• Biliopancreatic diversion with duodenal switch (BPD/DS): This is a two-part surgery that involves performing a sleeve gastrectomy and then connecting the end of the small intestine to the duodenum, bypassing most of the small intestine

Bariatric surgery can be very effective for long-term weight loss and can also improve or reverse obesity-related conditions such as diabetes, high cholesterol, and sleep apnoea. However, it is a major surgical procedure with potential risks and complications, such as bleeding, infection, and leaks in the gastrointestinal system. Patients should carefully consider the risks and benefits of bariatric surgery with their healthcare provider.

Emerging Applications of GLP-1 and GIP Drugs

While GLP-1 and GIP drugs are primarily known for their role in treating obesity and type 2 diabetes, research is exploring their potential applications in other disease areas. These include:

• Neurodegenerative diseases: Conditions such as Parkinson’s and Alzheimer’s disease involve protein misfolding and chronic inflammation. Studies have found that GLP-1 mimetics can cross the blood-brain barrier and have neuroprotective effects, including reducing oxidative stress and chronic inflammatory responses in the brain.
• Liver disease: GLP-1 and GIP receptor agonists have shown potential in improving liver health, particularly in individuals with nonalcoholic fatty liver disease (NAFLD).

These emerging applications highlight the versatility of GLP-1 and GIP drugs and their potential to address a wide range of health challenges beyond obesity and diabetes.

Conclusion

The field of anti-obesity drug development is rapidly evolving, with new therapies emerging that offer the potential for more effective and personalised weight management. While GLP-1 receptor agonists like semaglutide and tirzepatide have revolutionised the field, ongoing research is exploring new targets and combination therapies to address the limitations of existing medications. These advancements, such as the combination of semaglutide and bimagrumab, the development of triple-hormone receptor agonists like retratrutide, and the exploration of alternative delivery methods, hold promise for improving the lives of millions of people struggling with obesity and its related health complications.

However, it is crucial to acknowledge the potential side effects of these therapies, including gastrointestinal issues, pancreatitis, and the risk of pulmonary aspiration during anaesthesia. Patients should carefully consider the risks and benefits of these medications with their healthcare provider to determine the most appropriate treatment option.

Developing new anti-obesity drugs has significant implications for public health and the future of obesity management. These advancements offer hope for a more comprehensive and personalised approach to weight loss, potentially reducing the burden of obesity and its associated health problems.

The post The Evolving Landscape of Anti-Obesity Drugs appeared first on Medika Life.

And what I am reading.

And watching.

So, before we get to a new reason I don’t eat large meals late at night, I’ll address those questions.

What I’m Listening To

My interests are eclectic.

I recently listened to the Little Desk versions of songs from the Icelandic Grammy-nominated singer-songwriter Laufey:

I am also listening to Doechii on the Little Desk.

The lead singer, Jaylah Ji’mya Hickmon (known professionally as Doechii), is an American rapper, singer, and songwriter.

Joyful.

What I’m Watching

I’m watching Light of My Lion on Netflix in Japanese (with subtitles).

Hiroto, a city hall employee, cares for his autistic brother Michito after their parents’ deaths.

Their lives dramatically change when they take in a young boy named Lion, who leads them into an unexpected and life-altering incident.

On to the subject of the day.

Large Meals After 5

There are several reasons that I avoid eating large meals late in the evening.

I prefer a longer time between my last and first meals of the day.

However, research suggests another good reason to avoid big meals late in the day: Large meals after 5 p.m. could increase one’s risk of type 2 diabetes.

The study, conducted by researchers in Spain and the United States, found this:

Consuming more than 45 percent of daily calories after 5 p.m. may negatively impact glucose tolerance, especially in those with pre-diabetes or early type 2 diabetes.

Study Details

To investigate the effects of late eating, researchers studied 26 participants aged 50 to 75 who were overweight or obese and also had pre-diabetes or type 2 diabetes. Researchers divided the subjects into two groups:

• “Early eaters” consumed most of their daily calories before 5 p.m.
• “Late eaters” consumed 45% or more calories after 5 p.m.

Both groups maintained these eating patterns for 14 days, consuming similar total calories and macronutrients (carbohydrates, proteins, and fats).

However, late eaters consume nearly twice as many calories after 5 p.m., with a higher intake of fats and carbohydrates.

Why?

I suspect that eating later in the day leads to weight gain because most people are much less active at night (and not active at all as they sleep).

If I eat late at night, I consume calories when my body does not need them.

For me, this activity translates to this:

I want my latest meal of the day to be the lowest carbohydrate (and simple carbohydrate) meal.

My metabolism is most active between 10 a.m. and 5 p.m., so I avoid very large meals outside of that window.

My Take: Study Consequences

While we know that late-night eating can contribute to weight gain due to a slower metabolism during sleep, new research reveals a more significant concern.

This study indicates that eating late, specifically consuming more than 45% of your daily calories after 5 p.m., can disrupt blood sugar regulation (glucose metabolism), regardless of weight or overall calorie intake.

This disruption can lead to:

• Increased risk of developing type 2 diabetes: Poor blood sugar control is a major risk factor.
• Higher cardiovascular risk: Problems with glucose metabolism can negatively impact heart health.
• Chronic inflammation: This can contribute to various health issues over time.

These findings highlight the importance of what we eat and when we eat for optimal health.

Make a slight shift in your diet habits and reap the benefits.

The post One More Reason I Don’t Eat Large Meals Late at Night appeared first on Medika Life.

Like an endangered species, preventive medicine and chronic disease management—the US primary care system—face extinction. With nearly 30% of American adults lacking a source of care and 28 percent reporting delaying or not getting care due to cost, the consequences are far-reaching.  The focus on chronic disease prevention and addressing its root causes demands greater attention, as the health of the system—and the people it serves—depends on it. If we are frustrated about something, this is worth the outrage.

It has been almost impossible for elected officials, who too often look for singular villains, to grasp the extent of this system-wide dysfunction. This crisis extends beyond consumer comfort with technology or the cost of medicines. Primary care medicine—the basis for health delivery—is marginalized as an honored medical discipline. Somehow, we opt for a national health system prioritizing sick care over healthcare.

Primary care providers are grappling with burnout and inadequate compensation compared to their specialist counterparts, and the system often prioritizes paperwork over quality of care. Economics drives health delivery and access, and it’s simply not working to the advantage of consumers and primary care physicians.  

Finger-pointing and Senate HELP Committee photo ops cannot solve this nation’s care crisis. What’s needed is a fundamental shift in our approach to illness, prevention, and access—one that addresses the root causes of our failing primary care system and ensures that quality healthcare is accessible to all Americans, regardless of zip code or digital literacy. That will reduce our total health costs.

Obesity and Heart Disease: A Multigenerational Threat

America’s waistline is changing—we are adding notches to the nation’s belts. Obesity rates among younger Americans are climbing, creating an abundance of chronic diseases that once seemed confined to older generations. Alarmingly, heart disease, which had been in decline for decades, is creeping back up.

The invention of new weight-loss drugs like GLP-1 receptor agonists helps many struggling with chronic weight issues and mitigates some health risks. Yet, these drugs are not a complete answer to the challenge. They do not adequately address the underlying risks—heart disease, diabetes, and other chronic conditions—that require ongoing, consistent engagement with health professionals. Without this, even those who benefit from these medications – looking trim – may still end up battling old health challenges.

The persistent challenge of obesity across various age groups in the US, which hovers at +/- 40 percent, reinforces worrisome trends that impact people by age, race and region. A rate stable at 40 percent is not something to celebrate – it requires action. It’s a tipping point for illness.

Prediabetes: A Perfect Public Health Storm

Prediabetes is the nation’s silent epidemic. Close to 90 million adults—more than 1 in 3 Americans—have it, and 90% don’t know they do. Left unchecked, some 20 percent of these people “graduate” to Type 2 diabetes and other complications annually. The rise in obesity among younger populations only exacerbates this issue, setting the stage for an earlier onset of chronic diseases that worsen over time.

Prediabetes demands a dedicated behavior-focused treatment plan. Without significant lifestyle changes, individuals are on a fast track to diabetes and its life-altering complications. And yet, the primary care system—our first line of defense—is buckling under pressure, unable to provide the consistent support patients need. It’s not just the use of medications – it’s understanding that obesity is a multi-system condition and a unique disease that transcends more belt notches.

The Limitations of GLP-1 Drugs:

GLP-1 drugs do reduce weight and lower the risk of diabetes and heart disease. But they are not a substitute for comprehensive care. The underlying dangers—poor cardiovascular health, insulin resistance, and other metabolic issues—don’t disappear with weight loss alone. Without engagement with allied health professionals trained to address the complexities of obesity to monitor and address these risks, consumers will face new challenges despite these drugs’ initial success in losing pounds.

We live in what Katherine Saunders, MD, DABOM, a Weill Cornell Medicine’s Comprehensive Weight Control Center and co-founder of FlyteHealth, calls the “Obese-a-genetic” era.  Her efforts at FlyteHealth leverage the latest in science, technology, patient support, and a range of medications to individually tailor weight treatment based on a person’s unique biology alongside the complexity of obesity treatment:

“Overweight and obesity are misunderstood medical conditions that are more complex than calories in and calories out. The advice many patients receive—to eat less and exercise more—often fails to address the problem.”

Saunders and her colleagues are at the cutting edge of results-oriented care, but she is among the handful who have dedicated their careers to this pressing clinical discipline.

Walk-In Clinics are about Convenience

Convenience of care is essential to people’s well-being. Entrepreneurial internists have recognized this, creating “pop-up” vaccination and care centers to bring services closer to those in need and better work/life balance. But convenience alone isn’t enough. Urgent care clinics underscore one of the nation’s most pressing public health threats—the erosion of primary care—has reached a retail-like inflection point.

Walk-in clinics and telehealth check-ins are helpful but do not offer dedicated follow-up. They are geared to address the consumer’s immediate need and are not structured for the longitudinal engagement for the hard-to-tackle considerations that call for comprehensive support.

We are stuck between a system that focuses on its self-preservation and what is in our and national long-term interests – protecting our most important asset – our health.

The Rise of the Make American Health Again Movement

Primary care physicians, the cornerstone of preventive health, are becoming extinct as a medical profession species. The reasons are many: medical school debt driving doctors to higher-paying specialties, they are paid by the number of patients seen daily burnout, and the rise of retail clinics offering quick, transactional care.

While these clinics improve access, their focus is not on a long-term patient-physician relationship. This shift leaves a dangerous gap in the medical safety net, particularly for chronic conditions like obesity, prediabetes, and heart disease. Without a trusted health provider to guide them, patients are left to navigate their health journeys solo—often with devastating consequences.

Many are aghast at Robert F. Kennedy Jr.’s nomination to the Department of Health and Human Services as Secretary of the nation’s key organization setting national health policy. This justified anxiety centers on his stated positions on vaccines and his off-hand comments dismissing the importance of medicines in preventing more serious illnesses. However, his thoughts about America’s poor health report card grades deserve attention regardless of the outcome of the Senate confirmation hearings.

His Make America Healthy Again movement has an approach that deserves consideration: the need to tackle the chronic disease epidemic, which has become the leading cause of death in the US and, later, drives massive costs in hospitalization.

“There are some things that RFK Jr. gets right,” says Resolve to Save Lives CEO Dr. Tom Frieden, who was appointed Director of the Centers for Disease Control and Prevention during the Obama Administration. “We do have a chronic disease crisis in this country, but we need to avoid simplistic solutions and stick with the science.” Frieden made his comments in an NPR interview on the RFK Jr. nomination.

We need (much) more than medications and pop-up clinics to address America’s growing health crises. The health ecosystem must be reimagined to center around people’s health outcomes – not a one-size-fits-all approach to keeping them well. We must foster long-term patient-provider relationships, ensure easy access to understandable health data, emphasize nutrition and physical education in schools, and make care accessible to people across racial and generational lines.

As the ticking time bombs of obesity, prediabetes, and heart disease continue to warn, the urgency for change cannot be overstated. The frustration over the current complexity of access underscores what happens when we prioritize the system over prevention. Access to care isn’t just a convenience—it’s a matter of survival. To prevent the collapse of this fragile house of cards, we must act decisively and collaboratively to build a health system that sustains us all.

The post Conceptually, the “Make America Healthy Again Movement” Needs a Nod appeared first on Medika Life.